Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Int J Pediatr Otorhinolaryngol. 2018 Dec 21;118:124–127. doi: 10.1016/j.ijporl.2018.12.027

TABLE 1:

Characteristics of Study Participants

Characteristic
Age VGCV Started No (%)
  < 1 month 8 (50.0%)
  > 1 month 8 (50.0%)
Length of VGCV Treatment No (%)
  <6 weeks 6 (37.5%)
  >6 weeks, <6 months 7 (43.8%)
  6 months 3 (18.7%)
Method of cCMV diagnosis No (%)
  Urine 9 (56.2%)
  Saliva 7 (43.7%)
  Dried blood spot 4 (25%)
Extent of CMV disease No (%)
  Thrombocytopenia 3 (18.7%)
  IUGR 4 (25%)
  Hepatitis 4 (25%)
 CNS Involvement 10 (62.5%)
  Microcephaly 2 (12.5%)
  >2 Symptoms 5 (31.2%)
Neuroimaging results No (%)
  Normal 7 (43.8%)
  Abnormal 9 (56.2%)